Actelion

J&J Posts $17.7B in Revenue, Misses Estimates
Financial Performance

J&J Posts $17.7B in Revenue, Misses Estimates

Tepid growth in pharmaceuticals and consumer products held back first-quarter sales but the company is still confident it will meet its full-year guidance.
By Matthew Heller | April 19, 2017
Read More
J&J Boosts Drug Roster With $30B Actelion Deal
Strategy

J&J Boosts Drug Roster With $30B Actelion Deal

The largest acquisition in J&J's history gives it access to Actelion's portfolio of high-margin treatments for rare diseases.
By Matthew Heller | January 26, 2017
Read More